Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025;38(3):92-102.
doi: 10.1159/000545357. Epub 2025 Mar 28.

Healing Diabetic Foot Ulcers with Topical Timolol Improves Healed Epithelial Integrity

Affiliations
Randomized Controlled Trial

Healing Diabetic Foot Ulcers with Topical Timolol Improves Healed Epithelial Integrity

Rawlings E Lyle et al. Skin Pharmacol Physiol. 2025.

Abstract

Introduction: Diabetic foot ulcers (DFUs) are a common complication in diabetes, leading to high amputation risk and significant healthcare costs. Given topical timolol's emergence as a potential wound-healing agent, our study explored its impact on epidermal integrity.

Methods: This study was a post hoc analysis conducted as part of a randomized controlled trial at the Veterans Affairs Northern California Health Care System. Twenty patients, who had DFUs healed in the original trial, 10 in the timolol arm, and 10 in the placebo arm, were enrolled in the study. The primary outcome was transepidermal water loss, measured monthly for 3 months of post-healing using a closed-chamber device. The secondary outcome was re-ulceration rates over 1 year.

Results: Transepidermal water loss at 1, 2, and 3 months of post-healing was significantly lower in the timolol group than in the placebo group (p < 0.01). Linear mixed models identified contralateral foot transepidermal water loss as a significant predictor of healed diabetic foot ulcer site transepidermal water loss (estimate = 0.76, p < 0.001). The interaction between timolol treatment and months since healing significantly reduced transepidermal water loss over time (estimate = -2.2, p = 0.002). The use of a wheelchair was also associated with a significant decrease in transepidermal water loss (estimate = -7.7, p = 0.01). Initial transepidermal water loss values were higher in patients who re-ulcerated, but the difference was not statistically significant (p = 0.42). There was no difference in re-ulceration rates in this small pilot study.

Conclusion: Topical timolol significantly improved skin barrier function in healed DFUs, reducing transepidermal water loss. Although re-ulceration rates were not significantly different, the trend suggests potential benefits. Further studies with larger sample sizes and longer follow-up are needed to confirm these findings and explore transepidermal water loss's predictive value for re-ulceration.

Keywords: Beta-adrenergic receptor antagonism; Diabetic foot ulcer; Timolol; Transepidermal water loss; Wound healing.

PubMed Disclaimer

Publication types

LinkOut - more resources